Erlotinib and bevacizumab combination therapy for afatinib-refractory leptomeningeal carcinomatosis from EGFR-mutated lung cancer

Overview of attention for article published in International Cancer Conference Journal, January 2019

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 9 Dimensions

Readers on

mendeley: 23 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 145 followers.

PC | Erlotinib and bevacizumab combination therapy for afatinib-refractory leptomeningeal carcinomatosis from EGFR-mutated lung cancer. https://t.co/YF9IXJqG08

03 Jun 2019

Reply Repost Favourite